Compare Eastern Bankshares Inc. Common Stock (EBC) vs Relay Therapeutics Inc. Common Stock (RLAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eastern Bankshares Inc. Common Stock vs Relay Therapeutics Inc. Common Stock — how do they compare? Eastern Bankshares Inc. Common Stock trades at $20.77 (market cap $4.79B), while Relay Therapeutics Inc. Common Stock trades at $17.07 (market cap $3.81B). The key difference: Eastern Bankshares Inc. Common Stock is the larger of the two by market cap, and Eastern Bankshares Inc. Common Stock pays a 2.67% dividend while Relay Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eastern Bankshares Inc. Common Stock for 0 Days and Relay Therapeutics Inc. Common Stock for 5 Days on average.
| EBC | RLAY | |
|---|---|---|
Market Cap | $4.79B | $3.81B |
Volume | 1,740,716 | 1,706,150 |
Sector | Financials | Health |
52-Week High | $23.65 | $20.75 |
52-Week Low | $16.73 | $6.05 |
Typical Hold Time | 0 Days | 5 Days |
Enterprise Value | $5.07B | $2.93B |
Dividend Yield | 2.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eastern Bankshares (EBC) trades at $20.96, down 0.85% on the day, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.71, net income margin of 33.47%, and recent Q2 2026 EPS beat. Analyst consensus is bullish with a $25.60 price target. Recent news highlights institutional buying and upcoming Q3 2026 earnings.
The outlook is positive given solid profitability, attractive valuation, and analyst support. Key risks include integration challenges from recent acquisitions and interest rate sensitivity. Upside potential exists if earnings momentum continues, but investors should monitor net cash flow trends and competitive pressures.
Relay Therapeutics (RLAY) trades at $17.36, down 3.45% today, with technical indicators showing bearish momentum. The company remains in clinical-stage development with negative profitability metrics, including a -2,763.64% net income margin and -$276.48M net loss for 2025. Recent Q2 2026 earnings missed expectations with a loss of $0.41 per share, though the company continues advancing its oncology pipeline with Phase 3 trials planned for 2027.
Despite unanimous analyst buy ratings and a $26.25 consensus price target representing 51% upside, RLAY faces significant execution risk as a pre-revenue biotech. The stock's bearish technical setup and persistent cash burn require careful risk management, though institutional accumulation and AI-driven drug discovery platform provide long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Eastern Bankshares Inc. Common Stock
Eastern Bankshares, Inc. is the holding company for Eastern Bank, a Massachusetts-based bank operating more than 125 branches across eastern Massachusetts, southern and coastal New Hampshire, and Rhode Island, offering consumer and business banking along with wealth management through its Cambridge Trust divisions.
Read more on EBC →About Relay Therapeutics Inc. Common Stock
Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →
